PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral®
- 14 February 2007
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 119 (2), 197-206
- https://doi.org/10.1016/j.jconrel.2007.02.004
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Disease, destination, dose and delivery aspects of ciclosporin: the state of the artDrug Discovery Today, 2006
- Sustained release nanoparticulate formulation containing antioxidant-ellagic acid as potential prophylaxis system for oral administrationJournal of Drug Targeting, 2006
- Pharmaceutical Aspects of Polymeric Nanoparticles for Oral Drug DeliveryJournal of Biomedical Nanotechnology, 2005
- pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine AInternational Journal of Pharmaceutics, 2004
- MELATONINTransplantation, 1999
- The effect of physical barriers and properties on the oral absorption of particulatesAdvanced Drug Delivery Reviews, 1998
- THE INCREASED EFFICACY AND DECREASED NEPHROTOXICITY OF A CYCLOSPORINE LIPOSOME1,2Transplantation, 1994
- CyclosporinDrugs, 1993
- Generation of oxygen free radicals during the metabolism of cyclosporine A: a cause-effect relationship with metabolism inhibitionMolecular and Cellular Biochemistry, 1993
- First-pass metabolism of cyclosporin by the gutThe Lancet, 1991